U.K.-based SkyePharma's Flutiform, an inhaled combination of fluticasone and formoterol, has been launched in Germany by the company's partner, Mundipharma, as an asthma maintenance therapy.

DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Flutiform" report has been added to ResearchAndMarkets.com's offering. Flutiform ([fluticasone propionate + formoterol fumarate]; ...

LONDON (MarketWatch) -- U.K. drug delivery company SkyePharma PLC Tuesday said it has signed a deal with Kyorin Co. Ltd. (4569.TO) to develop and distribute its key experimental product, asthma ...

LONDON, UK, 1 September 2009 - SkyePharma PLC (LSE: SKP) today provides an update following a meeting held with the US Food and Drug Administration (FDA) to discuss the previously announced potential ...

Respiratory player Vectura can set aside its hopes of snagging a new COPD indication for its combination med Flutiform--at least for now. Tuesday, the U.K. company said that its ICS/LABA med had ...

Regulatory filing in Europe is expected during the first quarter of 2010. SkyePharma and Mundipharma have reported positive results from a Phase III trial with the inhaled asthma drug combination, ...

(Reuters) - British drugmaker Vectura said its asthma inhaler Flutiform had made favourable regulatory progress in Europe, and it can now apply for approvals through its partner. Vectura said its ...

(Reuters) - Drugmaker Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a late-stage trial to determine its ability to treat COPD, a type of lung disease, sending ...

SkyePharma’s shares were given a hefty boost yesterday after the company announced that a late-stage trial of Flutiform was a success, paving the way for the drug’s filing in Europe during the first ...